Navigation Links
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery

VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer patients. The data were presented on May 20, 2007 at the First International Congress of the International Association of Oral Oncology in Amsterdam, the Netherlands, by Dr. Eyal Talor, Senior VP of Research and Manufacturing at CEL-SCI Corporation.

Dr. Talor's presentation focused on the results obtained in CEL-SCI's final Phase II clinical trial of Multikine that was conducted in patients with head and neck cancer (oral squamous cell carcinoma -- OSCC). This final Phase II clinical trial was designed to assess thoroughly the positive safety and efficacy observations made in patients treated with Multikine in CEL-SCI's early Phase II trials. In the trial Multikine was given prior to standard care to recently diagnosed and not yet treated cancer patients.

The addition of Multikine to the first treatment (standard of care) of these patients resulted in a 33% improvement in the median overall survival at 3-1/2 years post-surgery, when compared to the survival results reported in 55 OSCC clinical trials published in the scientific literature between 1987 and 2007.

Multikine first-line treatment also resulted in an improvement of the 2- year local regional over the published local regional control rate. It is clinically recognized that recurrence of disease in head and neck cancer is associated with a very poor prognosis. Multikine treatment did not result in any severe adverse events (SAE) in this Phase II clinical trial and no SAEs related to Multikine have been reported in other trials conducted with Multikine either.

CEL-SCI received clearance from the United States Food and Drug Administration
'"/>




Page: 1 2 3

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: CEL SCI Presents Long Term Cancer Survival Data With Multikine
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
(Date:12/24/2014)... Dec. 23, 2014  Lockton Dunning Benefits, the ... Companies, announced the addition of Vice President ... Lockton Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... industry experience to the position.  Most recently, she ... at Diplomat Specialty Pharmacy, where she has held ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 ... plc (NASDAQ: ENDP ) (TSX: ENL), and ... announced today that they have submitted a New Drug ... U.S. Food and Drug Administration (FDA).  Buprenorphine HCl Buccal ... severe enough to require daily, around-the-clock, long-term opioid treatment ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... June 2 Medarex, Inc.,(Nasdaq: MEDX ... ongoing Phase 1,study of MDX-1106 (ONO-4538: development ... human anti-PD-1 antibody. Data presented from patients ... included the safety,tolerability and pharmacokinetic profile of ...
... presented at the 2008 ASCO Annual Meeting - - Conference call ... ... discuss results -, BRANFORD, Conn., June 1 CuraGen Corporation,(Nasdaq: ... of CR011-vcMMAE for the treatment of unresectable Stage III or,Stage IV melanoma. ...
Cached Medicine Technology:Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 2Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 3Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 2CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 3CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 4CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 5CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma 6
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
(Date:12/24/2014)... 25, 2014 The report “Stivarga (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is a drug which is used in the treatment ... administered and is also prescribed to patients who suffer ... FDA approved is a multi-kinase inhibitor and it blocks ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) -- ... year will be allowed to donate blood in the United States, ... on donations from men who have sex with men. The ... a new draft guidance in early 2015 that would ultimately open ... is changing its policy based on data from other countries that ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... by Massachusetts General Hospital (MGH) researchers to shield the ... radiation and chemotherapy has passed an important milestone. ... Sciences University (OHSU), published online in the journal Fertility ... to an FDA-approved agent called FTY720 preserved the fertility ...
... Reinberg HealthDay Reporter , MONDAY, Feb. 21 (HealthDay ... to 59 struggle with some kind of hearing loss, and ... older, a new study says. Yet much of that ... , Factors that contribute to hearing loss include working in ...
... high volume of mammograms may not detect more cancers but ... according to a new study published online and in the ... our expectations, we observed no clear association between volume and ... M.P.H., senior investigator at the Group Health Research Institute in ...
... This release is available in French . ... in your spit could reveal if you,re on the point ... and Robert-Paul Juster of the Centre for Studies on Human ... In addition to professional and personal suffering, burnout puts distressed ...
... medical errors isn,t quite as new as it seems. A ... at the turn of the last century, has turned up ... his suggestions for preventing those mistakes in the future. ... of Surgery , suggest that such open documentation may have ...
... , MONDAY, Feb. 21 (HealthDay News) -- Educating ... helps increase rates of skin self-examination and follow-up with ... States, an estimated 100,000 living kidney transplant recipients are ... tumors occurring in the skin that can spread to ...
Cached Medicine News:Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 2Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 3Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 4Health News:Hearing Loss Common Among Middle-Aged Adults: Study 2Health News:Hearing Loss Common Among Middle-Aged Adults: Study 3Health News:Higher volume reduces false positives in screening mammography 2Health News:Simple spit and blood tests might detect burnout before it happens 2Health News:Simple spit and blood tests might detect burnout before it happens 3Health News:Famed neurosurgeon's century-old notes reveal 'modern' style admission of medical error 2Health News:Education Might Help Kidney Recipients Spot Skin Cancer 2
... The new HF35-50 High Frequency Ultrasound ... high resolution, high frequency system available. The ... ultrasound biomicroscopy of the anterior segment with ... posterior segment ultrasound with a 20 MHz ...
... portable, digital A-scan system which provides easy-to-use ... high frequency, low noise probe and fast ... application of the probe along the visual ... display, storage of 5 different user profiles, ...
... Accurate, efficient and easy to use. The ... variety of regressive, theoretical, and adaptive IOL ... the patient. Convenient design features improve your ... hands-free operation, audible tone to minimize corneal ...
... In addition to three conventional measurement modes ... also incorporates a new axial length measuring ... by calculating sonic velocity for conversion at ... length by calculating each tissues sonic velocity ...
Medicine Products: